Evaluating the efficacy of topical tea tree oil versus preservative-free azithromycin in the treatment of dry eye disease associated with meibomian gland dysfunction: A randomized controlled trial focusing on tear interleukin levels
In brief
Tea tree oil gel clears meibomian glands in 64% versus 9% with azithromycin
In a 4-week masked trial of 44 adults with meibomian gland dysfunction-related dry eye, tea tree oil gel produced larger gains in tear break-up time, Schirmer scores and quality-of-life scores than preservative-free azithromycin, and 63.6% of patients achieved a normal gland grade versus 9.1% with azithromycin. The benefit was linked to a greater drop in tear IL-17, while azithromycin lowered IL-8 more; longer-term effects remain unknown.
- Journal
- Contact lens & anterior eye : the journal of the British Contact Lens Association (Q1)
- Published
- 20 September 2026
- Study design
- Randomized controlled trial
- Evidence level
- Level 1, High (CEBM 1b)
- Authors
- Dalia R El-Afify, Rewan H H Mahmoud, Fedaa A Kotkata, Tamer I Abdelhalim, Ehab Mohamed Elsayed Saad
- PMID
- 42764009
- DOI
- 10.1016/j.clae.2026.102843
Why clinicians should know about it
- Picked for Ophthalmology (top studies of the week, 27 September 2026): RCT comparing tea tree oil vs azithromycin for dry eye
Abstract
PURPOSE: Meibomian gland dysfunction (MGD) is a leading cause of dry eye disease (DED) and is associated with ocular surface inflammation characterized by elevated tear cytokines. METHODS: In this single-masked, randomized, parallel-group clinical trial, 50 adults with meibomian gland dysfunction (MGD)-associated dry eye disease were randomized (1:1) to receive topical tea tree oil (TTO) gel or preservative-free azithromycin 1% eye drops for 4 weeks, in addition to preservative-free lubricants. Six participants were lost to follow-up, leaving 44 participants who completed the 4-week assessment. Clinical outcomes included tear break-up time (TBUT), Schirmer I test, Ocular Surface Disease Index (OSDI), Dry Eye-Related Quality of Life Score (DEQS), meibomian gland dysfunction grading, and tear interleukin-8 (IL-8) and interleukin-17 (IL-17) concentrations measured at baseline and week 4. Between-group post-treatment comparisons were adjusted for baseline values using analysis of covariance. RESULTS: Both groups demonstrated significant post-treatment improvement in all clinical parameters (P < 0.001). The TTO group exhibited greater improvement in DEQS (median 10 vs 35; P < 0.001), TBUT (median 11 vs 8 s; P < 0.001), Schirmer I test (mean 14 ± 2 vs 9 ± 2 mm; P < 0.001), and achievement of MGD Grade 0 (63.6% vs 9.1%; P < 0.001). Post-treatment IL-17 concentrations were significantly lower in the TTO group (mean 27 ± 1 vs 44 ± 1 pg/mL; P < 0.001), whereas IL-8 reduction was more pronounced in the azithromycin group. Multivariable regression identified TTO treatment as an independent predictor of greater clinical improvement and IL-17 reduction. CONCLUSIONS: Tea tree oil was associated with greater short-term improvement in clinical outcomes than preservative-free azithromycin in patients with MGD-associated dry eye disease, particularly regarding tear film stability, meibomian gland function, and reduction of IL-17 concentrations. CLINICAL TRIALS REGISTRATION: The trial was registered at ClinicalTrials.gov (Identifier: NCT06921525).
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.